• Three new innovative instrument launches expand reach into further lab segments and sample preparation customers as QIAGEN strengthens market-leading position
   
  
• QIAsymphony Connect set to start phased launch in 2025, first customer sessions being held to highlight enhanced capabilities for oncology and genomics workflows
   
  
• QIAsprint and QIAmini on track for 2026 launches, expanding options for high- and low-throughput lab demands

VENLO, Netherlands, April 15, 2025--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments during 2025 and 2026 to expand and strengthen its portfolio for automated sample preparation.

These systems are designed to deliver new levels of efficiency and sustainability for laboratories worldwide and address different customer segments:

• QIAsymphony Connect, which marks the next generation of the flagship QIAsymphony with over 3,300 cumulative placements, is progressing well toward a phased launch to selected customers starting in 2025.
  
  Early customer sessions are being held at industry events during 2025 – including at the ESCMID (European Society of Clinical Microbiology and Infectious Diseases) conference in April 2025 in Vienna – to showcase the system’s enhanced capabilities in select settings upon request. The QIAsymphony Connect addresses pathogen nucleic acid extraction and various other applications including liquid biopsy, a non-invasive method for detecting cancer and other diseases through blood samples, as well as oncology, genomics, and clinical research workflows.
  
  The system can process up to 96 samples at a time and features improved automation capabilities for sample tracking and new applications, higher yield for increase in assay sensitivity and digital connectivity. It is compatible with QIAsphere, QIAGEN’s cloud-based platform for remote monitoring, software updates and instrument status. It is being designed for in vitro diagnostic (IVD) use globally, enabling compliant workflows in most countries and including the U.S. and Europe.
   
  
  
  
  
  
• QIAsprint Connect, on track for launch in 2026, marks the entry of QIAGEN into automated high-throughput sample processing.
  
  The first demonstrations of QIAsprint Connect have showcased the system’s potential to process up to 192 samples per run with less than 30 minutes of hands-on time, enabling labs to scale up to 600 samples per day. The system supports both pre-programmed and customizable protocols, and its consumables are designed with sustainability in mind, reducing plastic waste by up to 50%.
  
  "We were excited to test the QIAsprint. Its user-friendly design and ability to process large sample numbers efficiently is an ideal solution for laboratories like ours," said Kerstin Luxa of the Max Planck Institute for Plant Breeding Research in Cologne, Germany.
  
  The system supports a wide range of sample types, such as plant, microbial, soil, stool and human tissues, and is already being used to develop nine different applications. Its flexibility makes it ideal for labs working across various areas.
   
  
  
  
  
  
  
  
• QIAmini, also on track for launch in 2026, expands QIAGEN’s automation portfolio into the low-throughput segment.
  
  This cost-effective and low-complexity entry into automation brings the reliability of QIAGEN trusted kits to smaller labs and batch sizes. Ideal for replacing tedious pipetting, it delivers the reproducibility of automation with the flexibility to scale as needed.
  
  QIAmini complements QIAGEN’s portfolio alongside the updated QIAcube Connect and EZ2 Connect systems, offering automation options for even smaller-scale workflows.
  
  
  
  

"These new sample preparation systems underscore our commitment to helping labs operate more efficiently, sustainably and flexibly," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. "With QIAmini, QIAsprint Connect and QIAsymphony Connect, we are supporting customers with new ways to tackle complex challenges – from liquid biopsy to high-throughput screening – with smart, scalable solutions."

These upcoming launches build on recent enhancements across QIAGEN’s automation portfolio, including the upgraded QIAcube Connect and EZ2 Connect systems. Together, they reflect QIAGEN’s strategy to provide modular, scalable solutions in sample preparation that match evolving lab needs from small research settings to high-volume testing labs.

To learn more about QIAGEN’s portfolio of instruments for automated sample preparation, please visit: https://www.qiagen.com/de-de/product-categories/instruments-and-automation/nucleic-acid-purification

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading "Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Source: QIAGEN N.V.

Category: Life Sciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20250414679841/en/

Contacts

QIAGEN

Investor Relations
John Gilardi, +49 2103 29 11711
Domenica Martorana, +49 2103 29 11244
e-mail: ir@QIAGEN.com

Public Relations
Thomas Theuringer, +49 2103 29 11826
Lisa Specht, +49 2103 29 14181
e-mail: pr@QIAGEN.com